Close Menu

NEW YORK – Laboratory Corporation of America said Monday that it plans to offer two tranches of senior notes.

The company said it will use the proceeds for purposes including to purchase, redeem, or repay at maturity outstanding 2.625 percent senior notes that are due on February 1, 2020; repay some or all of the amounts outstanding under its term loan credit facilities; and purchase of up to $300 million of its outstanding $600 million of 4.625 percent senior notes due November 15, 2020 in a tender offer that the firm also announced on Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.